

8 November 2007



**National Institute for
Health and Clinical Excellence**

Sent via email

Midcity Place
71 High Holborn
London
WC1V 6NA

Tel: 020 7067 5800
Fax: 020 7067 5801

www.nice.org.uk

Dear Consultee/Commentator

Single Technology Appraisal

Febuxostat for the management of hyperuricaemia in patients with gout

I am writing to update you on the status of this Single Technology Appraisal (STA).

Following clarification of European regulatory timings for Febuxostat, its consideration at the Appraisal Committee meeting on 5 March 2008 has been cancelled. The Institute is currently discussing the timings for this appraisal and will inform you of new dates shortly.

If you have any other questions or queries please do not hesitate to also contact Natalie Bemrose on 020 7067 5930 or Natalie.Bemrose@nice.org.uk

Yours sincerely

Dr Carole Longson
Director
Centre for Health Technology Evaluation